Table 1.
Patient characteristics by initial antiretroviral treatment regimen
| Characteristics | Nevirapinea N=349 (74%) |
Efavirenz-baseda N=123 (26%) |
p |
|---|---|---|---|
| Gender, female | 245 (70.2%) | 80 (65.0%) | 0.288 |
| Age in years, median (IQR) | 34 (30–42) | 35 (31–41) | 0.504 |
| WHO Stages 3 and 4 | 322 (92.3%) | 97 (78.9%) | 0.000 |
| BMI (Kg/m2), median (IQR) | 20.3 (18.4–22.6) | 19.7 (18.0–21.6) | 0.079 |
| Hb g/dL, median (IQR) | 11.8 (10.5–13.0) | 11.7 (10.5–13.2) | 0.683 |
| CD4 count in cells/µl, median (IQR) | 101 (30–170) | 103 (33–159) | 0.912 |
| HIV RNA log copies/ml, median (IQR) | 5.4 (5.1–5.7) | 5.6 (5.2–5.8) | 0.019 |
a
Nevirapine-based (nevirapine+stavudine+lamivudine); efavirenz-based (efavirenz+zidovudine+lamivudine). WHO, World Health Organization; BMI, body mass index.